On May 2, 2022, Moshe Gerber was appointed as Chief Executive Officer, effective as of May 8, 2022.

Key Financial Terms and Metrics

The following discussion summarizes the key factors our management believes are necessary for an understanding of our consolidated financial statements.

We have not generated any revenues from product sales to date and we do not expect to generate revenues from product sales for the foreseeable future.

Our research and development costs include costs are comprised of:

? internal recurring costs, such as personnel-related costs (salaries, employee benefits, equity compensation and other costs), materials and supplies, facilities and maintenance costs attributable to research and development functions; and

? fees paid to external parties who provide us with contract services, such as preclinical testing, manufacturing and related testing and clinical trial activities.

Marketing expenses consist primarily of salaries, employee benefits, equity compensation, and other personnel-related costs associated with executive and other support staff. Other significant marketing expenses include the costs associated with professional fees to develop our marketing strategy.

Financial expenses consist primarily impact of exchange rate derived from re-measurement of monetary balance sheet items denominated in non-dollar currencies. Other financial expenses include bank's fees and interest on long term loans.

Revenues. We have not recorded any revenues to date.

Loss. Loss for the six months ended June 30, 2022 was $1,788,000, and is primarily attributable to research and development, marketing activities, general and administrative expenses

Financial Condition, Liquidity and Capital Resources

As of June 30, 2022, we had a total of $4,058,000 in cash resources and approximately $608,000 of liabilities, consisting of $370,000 of current liabilities from operations.

clinical studies (to the extent necessary), preliminary testing activities and

? the cost, timing and outcomes of regulatory related efforts for commercial

? the cost and timing of establishing sales, marketing and distribution

? the terms and timing of any collaborative, licensing and other arrangements

? the timing, receipt and amount of sales, profit sharing or royalties, if any,

? the cost of preparing, filing, prosecuting, defending and enforcing any patent

claims and other intellectual property rights; and

? the extent to which we acquire or invest in businesses, products or

technologies, although we currently have no commitments or agreements relating

We cannot be sure that future funding will be available to us on acceptable terms, or at all. Due to often volatile nature of the financial markets, equity and debt financing may be difficult to obtain.

We do not have any off-balance sheet arrangements.

© Edgar Online, source Glimpses